[Levilimab and baricitinib prescribing experience in outpatient COVID-19 patients' treatment].

A I Khripun A V StarshininY O AntipovaMar'yana A Lysenko Y V Urozhaeva O F Gavrilenko N A Rusantsova Andrej A Tyazhelnikov E Y Tikhonovskaya N V Okolot M V Sokolova Darya S Fomina E N Simonova Tat'yana S Kruglova Anton A Chernov A I Zagrebneva

Published in: Terapevticheskii arkhiv (2022)

The addition of levilimab or baricitinib to the therapy regimen for coronavirus infection during the outpatient phase has demonstrated a preemptive anti-inflammatory effect and reduced the probability of lung tissue damage progression.

Keyphrases

sars cov
anti inflammatory
primary care
oxidative stress
emergency department
stem cells
respiratory syndrome coronavirus
combination therapy
replacement therapy
bone marrow